.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BK02_Canagliflozin.Canagliflozin

Information

Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated for the treatment of type 2 diabetes mellitus in adults, improving glycemic control by reducing renal glucose reabsorption and promoting urinary glucose excretion. It is an approved, widely used oral antidiabetic agent.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers, both male and female, following a single 300 mg oral dose under fasting conditions.

References

1. Chen, X, et al., & Devineni, D (2015). Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. Clinical therapeutics 37(7) 1483–1492.e1. DOI:10.1016/j.clinthera.2015.04.015 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26048186

2. Devineni, D, et al., & Wajs, E (2016). Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants. Clinical therapeutics 38(1) 89–98.e1. DOI:10.1016/j.clinthera.2015.11.008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26687552

3. Devineni, D, et al., & Wajs, E (2015). Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Clinical therapeutics 37(3) 610–628.e4. DOI:10.1016/j.clinthera.2014.12.013 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25659911

Revisions

• 06/2025 initial generated model